TIDMPRTC
PureTech Health PLC
30 May 2017
30 May 2017
PureTech Health plc
PureTech Health's Vedanta Biosciences Granted U.S. Patent
Broadly Covering Methods of Treatment with Therapeutics Based on
Bacterial Spore Fractions of Microbiota Obtained From Human
Donors
PureTech Health plc ("PureTech", LSE: PRTC), an advanced,
clinical-stage biopharmaceutical company, is pleased to note that
the United States Patent and Trademark Office (USPTO) has issued a
new patent to Vedanta Biosciences. The latest issuance further
strengthens Vedanta Biosciences' leading intellectual property
position, broadly covering methods of treatment with therapeutic
products based on human microbiota-derived bacterial spore
fractions, including their use for the treatment of Clostridium
difficile infections, inflammatory bowel disease (IBD), and graft
versus host disease (GvHD), among others. The issued patent is
exclusively licensed to Vedanta under an agreement with the
University of Tokyo and provides coverage through at least
2031.
Bharatt Chowrira, President and Chief of Business and Strategy
at PureTech Health, said: "This issuance is particularly impactful
as we believe it grants Vedanta Biosciences the earliest priority
dates for the therapeutic use of human-derived spore fractions,
which is based in the pioneering groundbreaking work of Dr. Kenya
Honda, a scientific co-founder of Vedanta. We're pleased with the
addition of this latest patent to Vedanta Biosciences' foundational
IP portfolio in the microbiome field."
The full text of the announcement from Vedanta is as
follows:
Vedanta Biosciences Granted U.S. Patent Broadly Covering Methods
of Treatment with Therapeutics Based on Bacterial Spore Fractions
of Microbiota Obtained From Human Donors
CAMBRIDGE, Massachusetts, May 30, 2017- Vedanta Biosciences,
pioneering the development of a novel class of therapies designed
to modulate pathways of interaction between the human microbiome
and the host immune system, today announced that the United States
Patent and Trademark Office (USPTO) has issued U.S. Patent No.
9,662,381. The patent broadly covers methods of treatment with
therapeutic products based on human microbiota-derived bacterial
spore fractions, including their use for the treatment of
Clostridium difficile, inflammatory bowel disease (IBD), and graft
versus host disease (GvHD), among others. The issued patent is
exclusively licensed to Vedanta under an agreement with the
University of Tokyo and provides coverage through at least
2031.
"This newly issued patent enjoys, to the best of our knowledge,
the earliest priority dates for the therapeutic use of
human-derived spore fractions." said Bernat Olle, Ph.D., Chief
Executive Officer, "The expansion of our intellectual property
estate in the use of bacterial spores for the treatment of
autoimmune and infectious disease further strengthens Vedanta's
leading intellectual property portfolio in the human microbiome
field."
The patented technology is based on ground-breaking work by Dr.
Kenya Honda, a scientific co-founder of Vedanta. Dr. Honda's work
was described in landmark publications in Science and Nature. The
invention potentially provides an avenue for the treatment of a
variety of diseases including autoimmune diseases, such as IBD, and
infectious diseases, such as Clostridium difficile infection, with
compositions of bacterial spores obtained from human donors.
About Vedanta Biosciences
Vedanta Biosciences, a subsidiary of PureTech Health (LSE: PRTC;
www.puretechhealth.com), is pioneering development of a novel class
of therapies for immune and infectious diseases based on rationally
designed consortia of bacteria derived from the human microbiome,
with clinical trials expected to begin in 2017. Founded by PureTech
Health and a group of world-renowned experts in immunology and
microbiology, Vedanta Biosciences is a leader in the microbiome
field with capabilities to discover, develop and manufacture drugs
based on live bacterial consortia. Leveraging its proprietary
technology platform and the expertise of its team of scientific
co-founders, Vedanta Biosciences has isolated a vast collection of
human-associated bacterial strains and characterised how the immune
system recognises and responds to these microbes. This work has led
to the identification of human commensal bacteria that induce a
range of immune responses - including induction of regulatory T
cells and Th17 cells, among others - as well as the
characterisation of novel molecular mechanisms of microbial-host
communication. These advances have been published in leading
peer-reviewed journals including Science, Nature (multiple), Cell
and Nature Immunology. Vedanta Biosciences has harnessed these
biological insights as well as data from clinical translational
collaborations to generate a pipeline of programs in development
for infectious disease, autoimmune disease, inflammation and
immune-oncology. The clinical potential of therapeutic manipulation
of the microbiome has been validated by multiple randomised,
controlled trials in infectious disease and inflammatory bowel
disease. Vedanta Biosciences has a leading global intellectual
property portfolio in the microbiome field with patents issued by
the European Patent Office (EPO), Japan Patent Office (JPO) and the
United States Patent and Trademark Office (USPTO), and through
patent families exclusively licensed worldwide to Vedanta under an
agreement with the University of Tokyo.
Vedanta Biosciences' scientific co-founders have pioneered the
fields of innate immunity, Th17 and regulatory T cell biology, and
include Dr. Ruslan Medzhitov (Professor of Immunobiology at Yale),
Dr. Alexander Rudensky (tri-institutional Professor at the Memorial
Sloan-Kettering Institute, the Rockefeller University and Cornell
University), Dr. Dan Littman (Professor of Molecular Immunology at
NYU), Dr. Brett Finlay (Professor at the University of British
Columbia) and Dr. Kenya Honda (Professor, School of Medicine, Keio
University). Vedanta is backed by PureTech Health, Seventure,
Invesco Asset Management, and Rock Springs Capital.
About PureTech Health
PureTech Health (PureTech Health plc, PRTC.L) is an advanced,
clinical-stage biopharmaceutical company developing novel medicines
targeting serious diseases that result from dysfunctions in the
immune, nervous, and gastro-intestinal systems by intervening early
and addressing the underlying pathophysiology of disease. The
Company is advancing a rich pipeline that includes two pivotal or
registration studies expected to read out in 2017, multiple human
proof-of-concept studies and a number of early clinical and
pre-clinical programs. PureTech Health's growing research and
development pipeline has been developed in collaboration with some
of the world's leading scientific experts, who along with
PureTech's experienced team and a stellar Board identify, analyse
and advance very selectively the opportunities the Company believes
hold the most promise for patients. This experienced and engaged
team places PureTech Health at the forefront of ground-breaking
science and technological innovation and leads the Company between
and beyond existing disciplines. For more information, visit
www.puretechhealth.com or connect with us on Twitter
@puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
PureTech Health FTI Consulting
Allison Mead Ben Atwell, Matthew
+1 617 651 3156 Cole, Rob Winder
amead@puretechhealth.com +44 (0) 20 3727
1000
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAFSEDSLXEEF
(END) Dow Jones Newswires
May 30, 2017 02:02 ET (06:02 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Apr 2024 to May 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From May 2023 to May 2024